Neurocrine Biosciences (NBIX) Receivables (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Receivables of $887.0 million for Q2 2026, up 48.9% year-over-year from $595.7 million in Q2 2025, and up 15.48% on a QoQ basis from $768.1 million in Q1 2026.
Neurocrine Biosciences (NBIX) Receivables (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Receivables for 17 years, with the latest figure at $887.0 million in Q2 2026.
- Receivables for Q2 2026 came in at $887.0 million, up 48.9% year-over-year; the trailing twelve-month figure through Jun 2026 was $887.0 million (up 48.9% YoY), and the FY2025 annual result was $707.3 million, up 43.32% from the prior year.
- Receivables climbed to $887.0 million in Q2 2026, from $768.1 million in the prior quarter.
- Over five years, Receivables peaked at $887.0 million in Q2 2026 and troughed at $266.5 million in Q1 2022.
- A 5-year average of $499.0 million and a median of $465.8 million in 2024 frame the typical range for Receivables.
- The widest annual swing landed in 2022, when Receivables soared 88.97%; it then advanced 9.54% in 2024.
- A 5-year view of Receivables shows it stood at $354.7 million in 2022, then rose by 27.01% to $450.5 million in 2023, then advanced by 9.54% to $493.5 million in 2024, then jumped by 43.32% to $707.3 million in 2025, then climbed by 25.41% to $887.0 million in 2026.
- Per Business Quant data, the three most recent Receivables figures were $887.0 million in Q2 2026, $768.1 million in Q1 2026, and $707.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 3.07 Bn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | 3.49 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 1.57 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 5.84 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | 310.30 Mn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | 3.67 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 887.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.15 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | 1.08 Bn |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 456.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 887.00 Mn |
| Mar 31, 2026 | 768.10 Mn |
| Dec 31, 2025 | 707.30 Mn |
| Sep 30, 2025 | 728.00 Mn |
| Jun 30, 2025 | 595.70 Mn |
| Mar 31, 2025 | 516.00 Mn |
| Dec 31, 2024 | 493.50 Mn |
| Sep 30, 2024 | 481.10 Mn |
| Jun 30, 2024 | 468.20 Mn |
| Mar 31, 2024 | 463.30 Mn |
| Dec 31, 2023 | 450.50 Mn |
| Sep 30, 2023 | 425.90 Mn |
| Jun 30, 2023 | 393.20 Mn |
| Mar 31, 2023 | 396.00 Mn |
| Dec 31, 2022 | 354.70 Mn |
| Sep 30, 2022 | 305.10 Mn |
| Jun 30, 2022 | 281.70 Mn |
| Mar 31, 2022 | 266.50 Mn |
| Dec 31, 2021 | 187.70 Mn |
| Sep 30, 2021 | 166.60 Mn |